Enternext Welcomes Biocartis to Euronext Brussels


Brussels, 27 April 2015 – EnterNext, the Euronext subsidiary designed to promote and grow the market for SMEs, today welcomed Biocartis, an innovative molecular diagnostics company, to the regulated market of Euronext Brussels.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time PCR system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis (ticker code: BCART) issued 8,695,652 new shares at a reference price of €11.50 per share equivalent to €100 million. Based on the reference price, the total market capitalization of Biocartis at the opening stood at €450.2 million.

Rudi Pauwels, CEO of Biocartis, said : “The closing of this Offering, a week ahead of schedule, at the top of the price range and more than €650 million demand generated, underscores the strong belief in the potential of Biocartis and the appeal of our technology and strategy to institutional and retail investors, both in Belgium and internationally. We are delighted with this enthusiasm, and want to thank all our new investors for their support.

Vincent Van Dessel, CEO of Euronext Brussels, declared: “We want to extend a warm welcome to Biocartis as it lists on Euronext, in an IPO whose resounding success will help raise the company’s profile in Belgium and abroad. Euronext is delighted at this opportunity to be a partner to Biocartis as it moves ahead with new projects, which will benefit from the financing options offered by the capital markets.

Alain Baetens, Head of Listings of Euronext Brussels, said: “The IPO of Biocartis on Euronext Brussels is the largest Life Sciences transaction this year on the European markets, and ranks amongst the 10 largest IPOs over the last 10 years on Euronext Brussels. As such, it represents a new milestone for the Life Sciences franchise on Euronext, underpinning our market leadership in Europe, with over 30% of market share. The successful listing of Biocartis demonstrates the importance of the capital markets as a source of financing for innovative companies.

To celebrate the listing, Rudi Pauwels, CEO and founder of Biocartis, and Hilde Windels, CFO and General Manager of Biocartis, rang the bell in Brussels to open trading on Euronext’s European markets.

KBC Securities acted as sole global coordinator in the offering, KBC Securities, Kempen & Co and Petercam acted as joint bookrunners.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 1,930 listed issuers and around €6.8 trillion in market capitalisation as of end March 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.